Harnessing the immune system in acute myeloid leukaemia

详细信息    查看全文

• 作者：Rebecca Austin^aAuthor Vitae ; Mark J. Smyth^a ; ^b ; ¹ ; ^{mark.smyth@qimrberghofer.edu.au" class="auth_mail" title="E-mail the corresponding author}Author Vitae ; Steven W. Lane^a ; ^b ; ^c ; ¹ ; ^{Steven.lane@qimrberghofer.edu.au" class="auth_mail" title="E-mail the corresponding author}Author Vitae
• 关键词：Acute myeloid leukaemia ; Cancer immunosurveillance ; Immunoediting ; Neo-antigens ; Immunotherapy ; Immune checkpoints ; Immune suppression
• 刊名：Critical Reviews in Oncology and Hematology
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：103
• 期：Complete
• 页码：62-77
• 全文大小：2385 K

文摘

Acute myeloid leukaemia (AML) is an aggressive blood cancer caused by the proliferation of immature myeloid cells. The genetic abnormalities underlying AML affect signal transduction pathways, transcription factors and epigenetic modifiers. In solid tumours, it is emerging that the genetic landscape of the tumour has a direct effect on the anti-tumour immune responses and response to immunotherapeutic treatment. However, there remains little information as to whether genetic abnormalities affect anti-leukemic immune responses. This review discusses current knowledge of AML antigens and immune responses to AML with a particular focus on the role of T cells and natural killer cells. Understanding immune responses to AML has implications for the development and use of immunotherapies to treat AML patients with distinct genetic abnormalities.